Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare

Published: 11/02/2019
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
Source: WWW.PRNEWSWIRE.COM

TAIPEI, Taiwan, Feb. 11, 2019 /PRNewswire/ -- An exclusive license agreement for the commercialisation of Foresee Pharmaceutical's (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous depot formulations has been...

Read more
Related news
Comment
FACEBOOK